May 1, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Ampio Pharmaceuticals, Inc.
Acceleration Request for Registration Statement on Form S-3
File No. 333-237723
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Ampio Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 4, 2020, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Squire Patton Boggs (US) LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Leah Brownlee of Squire Patton Boggs (US) LLP at (216) 479-8549.
|
|
|
|
| Sincerely, | ||
|
| ||
|
AMPIO PHARMACEUTICALS, INC. | ||
|
| ||
| /s/ Daniel Stokely | ||
| Name: | Daniel Stokely | |
| Title: | Chief Financial Officer | |
|
| ||
|
| ||
| cc: | Leah Brownlee, Squire Patton Boggs (US) LLP | |
373 Inverness Parkway
Suite 200
Englewood, CO 80112 USA
www.ampiopharma.com